Patrick Miles Sells 43,459 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 43,459 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $11.95, for a total value of $519,335.05. Following the sale, the chief executive officer now owns 6,065,772 shares in the company, valued at $72,485,975.40. The trade was a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Patrick Miles also recently made the following trade(s):

• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00.

Alphatec Trading Down 0.5 %

NASDAQ ATEC opened at $11.36 on Monday. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The stock has a 50-day simple moving average of $10.27 and a 200 day simple moving average of $8.10. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.61 billion, a PE ratio of -8.88 and a beta of 1.43.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ATEC shares. Needham & Company LLC increased their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

Institutional Trading of Alphatec

Institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its stake in Alphatec by 0.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after acquiring an additional 1,120 shares during the last quarter. Atria Investments Inc boosted its position in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Alphatec by 1.3% during the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company’s stock worth $1,277,000 after purchasing an additional 1,746 shares in the last quarter. Entropy Technologies LP grew its holdings in shares of Alphatec by 14.9% in the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock valued at $120,000 after buying an additional 2,800 shares during the period. Finally, R Squared Ltd bought a new stake in shares of Alphatec in the 4th quarter valued at $29,000. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.